Hongkang Zhang
Senior Director & Head, Pian Therapeutics Quiver Bioscience
Seminars
Thursday 20th August 2026
Expanding Oligonucleotide Therapeutics into Pain: Platform-Enabled Targeting of NaV1
9:00 am
- Leveraging antisense oligonucleotides (ASOs) to modulate NaV1.7 expression as a novel non-opioid therapeutic strategy for chronic pain
- Positioning pain as an emerging and underexplored indication for oligonucleotide therapeutics beyond rare genetic and neurodegenerative diseases
- Applying AI and machine learning–enabled approaches to optimize ASO sequence and chemistry selection, improving target engagement and therapeutic index in preclinical development
